Claims
- 1. A pharmaceutical composition having gastric acid secretion inhibitory activity, in dosage unit form, comprising a pharmaceutical carrier and an effective amount of a thioamide compound of the formula: ##EQU4## in which: m is 0, 1, or 2;
- R.sub.1 is 2-pyridyl
- R.sub.2 is lower alkyl, allyl or cyclopropanemethyl;
- R.sub.3 is ##EQU5## NH-phenyl or NH-(CH.sub.2).sub.n -cycloalkyl, said cycloalkyl having 3-6 carbon atoms;
- R.sub.4 is hydrogen or lower alkyl;
- R.sub.5 and R.sub.6 are hydrogen or lower alkyl and
- n is 0 or 1
- or a pharmaceutically acceptable acid salt thereof.
- 2. A pharmaceutical composition of claim 1 in which R.sub.4 is hydrogen.
- 3. A pharmaceutical composition of claim 1 in which m is 0.
- 4. A pharmaceutical composition of claim 1 in which the thioamide compound is 2-methoxy-N-methyl-2-(2-pyridyl)thioacetamide.
- 5. A pharmaceutical composition of claim 1 in which the thioamide compound is 2-methoxy-N,N-dimethyl-2-(2-pyridyl)thiopropanamide.
- 6. A pharmaceutical composition of claim 1 in which the thioamide compound is present in an amount of from about 10 mg. to about 500 mg.
- 7. A method of inhibiting gastric acid secretion in an animal in need of said treatment which comprises administering to said animal an effective gastric acid secretion inhibiting amount of a thioamide compound of the formula: ##EQU6## in which: m is 0, 1 or 2;
- R.sub.1 is 2-pyridyl;
- R.sub.2 is lower alkyl, allyl or cyclopropanemethyl;
- R.sub.3 is ##EQU7## NH-phenyl or NH-(CH.sub.2).sub.n -cycloalkyl, said cycloalkyl having 3-6 carbon atoms;
- R.sub.4 is hydrogen or lower alkyl;
- R.sub.5 and R.sub.6 are hydrogen or lower alkyl and
- n is 0 or 1
- or a pharmaceutically acceptable acid addition salt thereof.
- 8. A method of claim 1 in which R.sub.4 is hydrogen.
- 9. A method of claim 1 in which m is 0.
- 10. A method of claim 1 in which the thioamide compound is 2-methoxy-N-methyl-2-(2-pyridyl)thioacetamide.
- 11. A method of claim 1 in which the thioamide compound is 2-methoxy-N,N-dimethyl-2-(2-pyridyl)thiopropanamide.
- 12. A method of claim 1 in which the thioamide compound is administered in a daily dosage of from about 10 mg. to about 2500 mg.
Parent Case Info
This is a division of application Ser. No. 386,898, filed Aug. 9, 1973 now U.S. Pat. No. 3,907,814, which is a continuation-in-part of Ser. No. 284,375, filed Aug. 28, 1972, now abandoned, which is a continuation-in-part of Ser. No. 248,512, filed Apr. 28, 1972, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3825547 |
Loev |
Jul 1974 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
386898 |
Aug 1973 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
284375 |
Aug 1972 |
|
Parent |
248512 |
Apr 1972 |
|